Sam Chun Dang Pharm Shares Plunge 29.79% the Day After Hitting the Upper Limit: FDA Pre-ANDA Is Not Approval
이 포스팅은 쿠팡 파트너스 활동의 일환으로, 이에 따른 일정액의 수수료를 제공받습니다.
Sam Chun Dang Pharm closed at the daily upper price limit on 2026-07-20, but on the following trading day, 21, its shares finished at KRW 167,800, down 29.79% from the previous session.
The rally began after the company announced that it had received a Pre-ANDA response letter from the U.S. Food and Drug Administration (FDA) concerning the development of a generic oral semaglutide product.
However, a Pre-ANDA response letter is not formal marketing approval. The stage confirmed so far is closer to a preliminary consultation with the FDA on the development strategy before submitting an approval application.
The information is current as of 2026-07-22 Korea Standard Time. Prices and trading conditions may change when the market reopens.
How Far Did the Share Price Fall the Day After Hitting the Upper Limit?
Sam Chun Dang Pharm closed at KRW 184,100 on July 16.
Following the FDA-related announcement, its shares rose to KRW 239,000 on July 20. Compared with the closing price on 16, this represented an increase of KRW 54,900, or approximately 29.82%.
However, on 21, the shares initially climbed to KRW 254,000 before increasing selling pressure pushed them down to KRW 167,500 during the session. The final closing price was KRW 167,800.
| Category | Share Price | Comparison |
|---|---|---|
| Closing price on July 16 | KRW 184,100 | Baseline |
| Closing price on July 20 | KRW 239,000 | +29.82% compared with 16 |
| Intraday high on July 21 | KRW 254,000 | +6.28% compared with the closing price on 20 |
| Intraday low on July 21 | KRW 167,500 | Near the daily price limit |
| Closing price on July 21 | KRW 167,800 | -29.79% from the previous session |
A direct calculation shows that the share price fell by KRW 71,200 per share between the closing price of KRW 239,000 on July 20 and the closing price of KRW 167,800 on 21.
An even more striking comparison is with July 16. Before the stock hit its upper price limit, its closing price was KRW 184,100. Yet the closing price on 21 was KRW 16,300 lower. After a sharp rise followed by a steep decline over two days, the shares ended approximately 8.85% below their pre-announcement price.
A stock that falls by the same percentage as its previous rise does not return to its original price. This is because the percentage decline is calculated from the higher price reached after the increase.
What Does an FDA Pre-ANDA Response Letter Mean?
ANDA stands for 'Abbreviated New Drug Application.' It is an application submitted to the FDA for the review and potential approval of a generic drug in the United States.
The FDA explains that once an ANDA is approved, the generic product can be manufactured and marketed in the United States. Applicants must demonstrate that their product is comparable to the original drug in dosage form, strength, route of administration, quality, performance, and other relevant characteristics.
Rather than repeating large-scale safety and efficacy clinical trials from the beginning in the same manner as a new drug, the review generally places significant emphasis on bioequivalence data and other evidence showing that the generic product works similarly to the original drug.
What Sam Chun Dang Pharm announced this time was not an ANDA approval. It was the receipt of a Pre-ANDA response letter following discussions with the FDA about its development strategy before submitting an ANDA.
The stages can be distinguished as follows.
| Stage | What Is Reviewed or Discussed | Marketing Authorization Status |
|---|---|---|
| Pre-ANDA consultation | Preliminary discussions about development strategy and required submission materials | Not approval |
| ANDA submission | Submission of generic drug quality and equivalence data to the FDA | Application submission and review process |
| FDA review | Evaluation of submitted data and manufacturing and quality requirements | Outcome not yet determined |
| ANDA approval | FDA approves the product as a marketable generic drug | Marketing permitted in the United States |
Therefore, 'receiving a response from the FDA' does not mean the same thing as 'receiving FDA approval.'
The company maintains that the response has substantially reduced regulatory uncertainty surrounding its development pathway. Meanwhile, market participants have pointed to the need to recognize that the full response letter, specific data requirements, and the possibility of additional testing have not all been publicly disclosed.
Why Did Expectations Weaken Just One Day After the Announcement?
The first reason is the gap between the stage announced and actual regulatory approval.
Although Pre-ANDA consultation can be a useful part of drug development, it does not mean that the product has received final approval or is ready for launch. Further procedures remain, including ANDA submission and acceptance, possible requests for additional documentation, bioequivalence assessment, and manufacturing quality review.
The second reason is that the company did not disclose the complete response letter.
The company says it is difficult to release the entire document because it contains confidential discussions involving proprietary technology and regulatory strategies. While protecting commercially sensitive information is a legitimate concern, investors must assess the document's conditions and limitations using only the company's summarized explanation.
The third reason is that controversies surrounding previous announcements and disclosures continue to affect investor sentiment.
Sam Chun Dang Pharm previously faced controversy over the interpretation of contracts and the adequacy of disclosures after announcing agreements related to oral semaglutide and projected revenue figures. Its history of being designated by the Korea Exchange as a company responsible for unfaithful disclosure has also been cited as a reason for subjecting the latest announcement to closer scrutiny.
The company's announcement describes progress in development; it is not an official FDA approval document. Keeping these two distinctions clear is central to understanding the issue.
How Would the Value of a Holding of 10 Shares Have Changed?
For a simple comparison, consider closing prices alone, excluding fees, taxes, and the actual purchase price.
If an investor held 10 shares at the closing price of KRW 239,000 on July 20, the holding would have been valued at KRW 2,390,000.
Applying the closing price of KRW 167,800 on 21, the holding would have been worth KRW 1,678,000. The difference over one day was KRW 712,000.
| Reference Point | Value of 10 Shares |
|---|---|
| Based on the closing price on July 20 | KRW 2,390,000 |
| Based on the closing price on July 21 | KRW 1,678,000 |
| Difference in valuation | -KRW 712,000 |
Suppose an investor purchased 10 shares at the intraday high of KRW 254,000 on 21. The purchase amount would have been KRW 2,540,000. The difference between that amount and the holding's value at the same day's closing price would have been KRW 862,000, equivalent to approximately 33.94%.
This does not represent an actual investor's realized profit or loss. The outcome depends on when the shares were purchased, whether they were sold, and applicable fees and taxes.
For stocks experiencing repeated short-term price swings near the daily price limits, investors should first examine how far the underlying information has been verified rather than focusing solely on the apparent significance of positive news.
What Announcements Should Investors Watch Next?
At the current stage, it is difficult to predict the direction of the share price with certainty. The available information alone cannot establish whether the stock will rebound or decline further in the next trading session.
Instead, investors can monitor the form and substance of subsequent disclosures.
Whether the company provides specific explanations of the FDA response letter's key conditions and additional requirements
Whether the bioequivalence testing plans and results for the generic oral semaglutide product are disclosed
Whether the actual submission of an ANDA and its receipt by the FDA are officially confirmed
Whether information about partners, sales territories, contract amounts, and revenue-sharing terms is confirmed through regulatory disclosures
Whether product information becomes available in official FDA databases following approval
It is particularly important to distinguish between press releases and corporate regulatory disclosures.
A press release is a document in which a company explains the significance of its achievements. A corporate regulatory disclosure communicates material information affecting investment decisions to the market under prescribed formats and responsibilities.
When a significant contract or regulatory development is announced, it is safer to check not only the wording on the company's website but also whether the same information has been filed through the Korea Exchange's KIND disclosure system and the Financial Supervisory Service's electronic disclosure system.
Three Distinctions That Matter in This Case
Confirmed facts: Sam Chun Dang Pharm announced that it had received a Pre-ANDA response letter, its shares reached the upper price limit on July 20, and they subsequently closed down 29.79% on 21.
The company's interpretation: The response has substantially reduced regulatory uncertainty concerning the development pathway for its generic oral semaglutide product.
What remains unconfirmed: Whether the ANDA will ultimately be submitted and approved, whether additional tests or supplementary materials will be required, and the actual timing of a U.S. launch and the scale of future revenue.
Confusing these three categories could make a preliminary consultation appear equivalent to regulatory approval or, conversely, lead observers to dismiss all development progress as meaningless.
Pre-ANDA is not approval, but it is a stage in the development process. The commercial value of the project must be assessed through subsequent submissions and the results of the FDA review.
Frequently Asked Questions
Has Sam Chun Dang Pharm Received FDA Approval?
No. The publicly available information concerns the company's announcement that it received a Pre-ANDA response letter related to the development of a generic oral semaglutide product. This must be distinguished from formal ANDA approval.
Does an ANDA Mean That No Clinical Testing Is Required at All?
Generally, generic drug developers do not have to repeat the entire clinical development program required for a new drug. However, bioequivalence evidence demonstrating that the generic product works equivalently to the original drug, along with quality and manufacturing documentation, is required. The FDA may also request additional information.
Does the Sharp Decline Mean a Rebound Is Now More Likely?
A sharp decline alone cannot determine whether a rebound will occur. Prices may change depending on progress in the FDA regulatory process, official disclosures, trading supply and demand, and broader market conditions.
This article presents publicly available information in an accessible format and does not recommend buying or selling any particular stock or promise investment returns. Regulatory approval timelines and projected revenues for biotechnology companies can vary significantly depending on development outcomes, regulatory decisions, and contractual terms.
The prices in this article were cross-checked against Korea Exchange-based reporting on July 20–21, while the distinction between Pre-ANDA and formal approval was reviewed using the FDA's official explanation of the ANDA process. Information concerning financial regulators reflects what had been confirmed through the reporting period of July 22. U.S. Food and Drug Administration+3Korea Economic Daily+3The Economist+3
※ This article is provided for reference to help readers understand market developments and does not constitute investment advice regarding any particular stock or asset. All final investment decisions and associated responsibilities rest with the individual investor.
이 포스팅은 쿠팡 파트너스 활동의 일환으로, 이에 따른 일정액의 수수료를 제공받습니다.